Vanguard reports 10.99M Biogen shares (7.48%)
Biogen Inc ownership filing: Vanguard Capital Management reports beneficial ownership of 10,989,562 shares of Biogen common stock, representing 7.48% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Biogen Inc ownership filing: Vanguard Capital Management reports beneficial ownership of 10,989,562 shares of Biogen common stock, representing 7.48% of the class. The filing shows Vanguard has sole voting power for 1,452,145 shares and sole dispositive power for 10,989,562 shares.
The Schedule 13G statement describes holdings across Vanguard business units and notes the reported interests include shares held for Vanguard funds and other managed accounts.
Insights
Vanguard owns 7.48% of Biogen, a visible institutional stake.
The filing shows 10,989,562 shares beneficially owned and a 7.48% stake, reported on a Schedule 13G indicating passive, long‑term ownership. The report aggregates holdings across Vanguard Capital Management and affiliated advisory units.
Key dependencies include fund flows and client mandates that determine whether Vanguard's position remains passive; future amendments would appear if voting or disposition powers change.
Disclosure clarifies voting and dispositive authority within Vanguard's business units.
The statement specifies sole voting power for 1,452,145 shares and sole dispositive power for 10,989,562 shares, with no shared powers reported. It follows SEC Release No. 34-39538 aggregation guidance for affiliated advisory divisions.
Any shift from passive to active status or changes in voting power would require an updated filing; timing of such changes is not provided in the excerpt.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owned financial
sole dispositive power regulatory
aggregation guidance (SEC Release No. 34-39538) regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does 'sole dispositive power' mean in this filing?
Is this Schedule 13G an active or passive disclosure?
When was the Schedule 13G signed and filed?
AI-generated analysis. How Rhea-AI works. Not financial advice.